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Objective: To investigate the clinical efﬁciency of noninvasive prenatal test (NIPT) identifying fetal
chromosomal aneuploidies.
Materials and methods: In the present study, 917 women with high-risk pregnancies were invited to
participate in an NIPT trial based on an Illumina HiSeq massively parallel sequencing platform. Abnormal
cases in NIPT were validated by karyotyping and ﬂuorescence in situ hybridization (FISH) analysis. All of
the participants' infants were examined clinically and followed up for at least 6 months.
Results: A total of 35 (3.82%) high-risk pregnancies were detected with abnormal results in NIPT, which
included 25 cases (2.73%) of trisomy 21 (Tri21), four cases (0.44%) of trisomy 18 (Tri18), four cases (0.44%)
of Turner syndrome (45, X), one cases (0.11%) of Klinefelter's syndrome (47, XXY), and one cases (0.11%)
with lower X chromosome concentration. Further validation indicated that one case of Tri18 and the case
with lower X chromosome concentration were false positive results (0.22%) in NIPT. Furthermore, it was
found that the false positive case with lower X chromosome concentration in NIPT was caused by
maternal sex chromosomal mosaicism (45, X and 46, XX).
Conclusion: Our ﬁndings indicated that maternal mosaicism of sex chromosome could cause discordant
sex chromosomal aneuploidies associated with NIPT. We highly recommended that maternal karyotype
should be conﬁrmed for the cases with abnormal results in NIPT.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Chromosome aneuploidies, mostly characterized by trisomy 21
(Tri21), trisomy 18 (Tri18), trisomy 13 (Tri13), and monosomy X [1],
lead to medical conditions among neonates requiring specialized
medical care and result in emotional and ﬁnancial challenges to
families [2]. The aneuploidies usually occur in one out of every 160
live births and account for 6e11% of all stillbirths and newborntal Diagnosis, Lianyungang
Lianyungang, Jiangsu 222001,
bstetrics & Gynecology. Publisheddeaths [3,4]. Moreover, the risk of giving birth to a child with
chromosomal abnormalities, especially Down syndrome, increases
with maternal age [5]. Early diagnosis during the course of preg-
nancy may inform the family about the potential for a fetus with
chromosomal aneuploidy. Therefore, early prenatal screening and
diagnosis to detect the most common trisomy are indispensable.
Chromosome aneuploidies are traditionally veriﬁed through
invasive diagnostic procedures including amniocentesis and um-
bilical cord blood or chorionic villus sampling [5,6]. These invasive
diagnostic procedures require skilled techniques and carry an
approximately 0.5e1% risk of miscarriage [5]. In addition, the pro-
cedures for conventional prenatal diagnosis take lengthy waiting
periods (usually about 14 days). With a culture failure rate of ~1%,
many pregnant women dread the sampling and waiting periodsby Elsevier Taiwan LLC. All rights reserved.
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circulating blood [9], which led to the development of noninvasive
prenatal test (NIPT) based on analyzing fetal cfDNA in the mother's
blood. NIPT is a new platform for prenatal screening and diagnosis
of trisomy syndromes with high accuracy and low risk [10e12].
Recently, the use of fetal cfDNA had been reported for the pre-
natal diagnosis of achondroplasia and myotonic dystrophy, deter-
mination of fetal sex, and genotyping of fetal rhesus D [13e16].
However, several problems had restricted the clinical use of the
analysis of fetal cfDNA, such as the low concentration of fetal cfDNA
in the maternal circulation and the difﬁculty in distinguishing fetal
from maternal chromosomes [17,18]. Moreover, a signiﬁcant num-
ber of false positive results from NIPTs had underlain the biological
reasons, including conﬁned placental mosaicism (CPM), maternal
mosaicism, co-twin demise, and maternal malignancy [19].
Therefore, more information about NIPT, as well as improvements
in its effectiveness, should be made available to pregnant women.
Since 2012, NIPT have been offered as an additional option in
our hospital for high-risk pregnant women needing to conﬁrm
chromosome aneuploidies. Up until now, 917 high-risk pregnant
women from our hospital have participated in an NIPT trial and two
discordant results were found. These ﬁndings will provide useful
information about NIPTs for further improvements.Patients and methods
Patients
From our prenatal clinics, pregnant women with gestational
ages between 14 weeks and 26 weeks meeting any one of the
following conditions were considered as high-risk pregnancies: (1)
abnormal maternal screening of AFP and free beta-human chori-
onic gonadotropin; (2) advanced maternal age ( 35 years); (3)
abnormal ultrasound ﬁndings; (4) abnormal amniotic ﬂuid volume;
(5) adverse pregnancy history obtained from medical records; and
(6) single umbilical artery. Within a 2-year period (January 2012 to
December 2013), a total of 917 high-risk pregnancies were identi-
ﬁed, and all of them agreed to participate in the NIPT trial. After
childbirth, their infants were examined clinically and followed up
for at least 6 months. This project was approved by the Hospital
Ethics Committee and informed consent was obtained from each
participant.NIPT
Approximately 10 mL blood from each high-risk pregnant
woman was collected into a purple-top tube containing EDTA. The
blood sample was immediately centrifuged at 1600g for 10 minutes
at 4C. The plasma portion was centrifuged at 16,000g for 10 mi-
nutes to minimize any additional release of maternal DNA. TheTable 1








Abnormal maternal serum screening 521 (56.82) 10 (1.09) 5 (0.55
Advanced maternal age 300 (32.72) 13 (1.42) 9 (0.98
Abnormal ultrasonic ﬁnding 6 (0.65) 1 (0.11) 1 (0.11
Abnormal amniotic ﬂuid volume, adverse
pregnancy history, or single umbilical artery
90 (9.81) 11 (1.20) 10 (1.09
Total 917 (100) 35 (3.82) 25 (2.73plasma specimens were frozen on dry ice and sent to a commercial
lab that specialized in NIPT (www.berrygenomics.com). The NIPT
procedures, including DNA extraction, library construction, whole-
genome sequencing, and data analysis, were carried out according
to protocols published elsewhere [10]. In brief, plasma DNA was
extracted from 1 mL of the plasma using the QIAamp Circulating
Nucleic Acid kit fromQiagen (Hilden, Germany). Then, the resulting
plasma DNA was used as the input DNA to make a library for
sequencing. Plasma DNA libraries were indexed using 6 bp indexing
oligos, quantitated by Kapa SYBR fast qPCR kit from Kapa Bio-
systems (Woburn, MA, USA), pooled, and loaded into one lane in a
v2 Illumina HiSeq2000 ﬂow cell (Illumina, USA). Clustering and
sequencing were conducted according to Illumina's instruction,
using the single-ended 43 bp sequencing protocol. Finally, the se-
quences were binned for each sample according to the index and
mapped to the unmasked human genome sequence (hg19) using
the software SOAP2 (obtained from soap.genomics.org.cn/), and the
z-score for each chromosome was calculated to judge abnormality
referencing to the normalized chromosome representation.Karyotyping and ﬂuorescence in situ hybridization
For each abnormal woman in NIPT, approximately 20 mL of
amniotic ﬂuid and 10 mL of maternal peripheral blood were
collected. Conventional karyotyping analysis and ﬂuorescence in
situ hybridization (FISH) were performed for further validation.
Karyotyping was processed using a conventional Giemsa banding
(G-binding) method [20], and FISH was performed according to the
method previously established [21].Results
NIPT
A total of 917 high-risk pregnant women were recruited for the
NIPT trial. Their ages ranged from 18 years to 46 years with the
following distribution: 18e25 years (299, 22.86%), 26e35 years
(318, 40.00%), and 36e46 years (300, 37.14%). Among them, the
number of women with advanced maternal age, abnormal
maternal serum screening, abnormal ultrasonic graphic ﬁndings,
and other conditions (with abnormal amniotic ﬂuid volume,
adverse pregnancy history, or single umbilical artery) were 300
(32.72%), 521 (56.82%), 6 (0.65%), and 90 (9.81%), respectively
(Table 1). After NIPT, 34 (3.71%) high-risk pregnancies were found
with fetal aneuploidies, which included 25 cases (2.73%) of Tri21,
four cases (0.44%) of Tri18, four cases (0.44%) of Turner syndrome
(45, X), and one case (0.11%) of Klinefelter's syndrome (47, XXY)
(Table 1). Furthermore, one woman (0.11%) was found with lower X
chromosome concentration than expected. This ﬁnding could have
been due to fetal Turner syndrome, but this was considered to beNumber
Abnormality discovered by NIPT






) 1 (0.11) 3 (0.33) 0 (0) 1 (0.11)
) 2 (0.22) 1 (0.11) 1 (0.11) 0 (0)
) 0 (0) 0 (0) 0 (0) 0 (0)
) 1 (0.11) 0 (0) 0 (0) 0 (0)
) 4 (0.44) 4 (0.44) 1 (0.11) 1 (0.11)
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cases of fetal Turner syndrome. Therefore, the laboratory suggested
that the most likely cause was maternal mosaicism. All of the 35
women (3.82%) with abnormal ﬁndings above included nine with
advanced maternal age, 14 with abnormal maternal serum
screening, one with an abnormal ultrasound ﬁnding, and 11 with
other conditions (5 with abnormal amniotic ﬂuid volume, 3 with
adverse pregnancy history, and 3 with single umbilical artery).
For the 35 women with abnormal results in NIPT, full kar-
yotyping analysis of their amniotic ﬂuid was performed for further
validation. The karyotyping results of 33 cases were consistent with
NIPT results. However, one case identiﬁed as Tri18 in NIPT was
detected as normal in karyotyping analysis (Figure 1A). Addition-
ally, the case with lower X chromosome concentration in NIPT was
detected as normal in karyotyping analysis. For the remaining 882Figure 1. Validation of the false positive trisomy 18 (Tri18) in noninvasive prenatal test
(NIPT) through (A) full karyotyping and (B) ﬂuorescence in situ hybridization (FISH) of
the amniotic ﬂuid cell. Two chromosomes 18 were marked with red arrows in the
karyotype (A). Under ﬂuorescence microscope, chromosomes 18, X and Y were hy-
bridized with probes labeled with blue, red and green ﬂuorescence, respectively (B).normal cases in NIPT, no visible chromosomal abnormality of ba-
bies was detected in the subsequent clinical follow up (once/
month) from birth to 6 months.
Further validation of two special cases
For the woman with discordant results in NIPT (Tri18) and
karyotyping analysis (normal), FISH for chromosome 18 was per-
formed using cells from the amniotic ﬂuid. Under the ﬂuorescence
microscope, only two ﬂuorescence probe signals for chromosome
18 were detected in each cell (Figure 1B), which indicated that the
fetus of the woman was normal disomy 18. Moreover, no
morphological abnormality of the fetus was detected in the
following ultrasonic diagnosis. Ultimately, the woman gave birth to
a full term boy, and no visible chromosomal abnormality was found
in karyotyping analysis of the baby's peripheral blood (data not
shown) and subsequent clinical follow up.
For the woman with lower X chromosome concentration in
NIPT, full karyotyping analysis of her peripheral blood was per-
formed for further veriﬁcation. Among the 40 G-banded karyotypes
randomly selected, 28 (70%) were normal (46, XX), but 12 (30%)
were abnormal (45, X) (Figure 2), which indicated that the woman
presented maternal mosaicism for chromosome X (45, X and 46,
XX). However, the woman also gave birth to a full term boy, and no
visible chromosomal abnormality was found in karyotyping anal-
ysis of his peripheral blood (data not shown) and subsequent
clinical follow up.
Discussion
Since fetal cfDNA was ﬁrst discovered in plasma from pregnant
women in 1997 [9], NIPTs of fetal aneuploidies dependent on fetal
cfDNA had attracted increasing attention. Now, fetal wholeFigure 2. Validation of maternal mosaicism of sex chromosome (45, X and 46, XX)
through maternal karyotyping. (A) chromosome X was marked with the red arrow in
karyotypes and (B) the percentage of each karyotype was described in column graph.
L. Wang et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 527e531530chromosome aneuploidy can be accurately detected frommaternal
blood by NIPT using massively parallel sequencing [10]. Based on
massively parallel sequencing, NIPT is considered as a highly ac-
curate protocol for the prenatal detection of Down syndrome and
Tri18. This novel protocol has higher detection and lower false
positive rates than traditional effective screening protocols (with
false positive rates of 2e5%) based on the combination of maternal
age, ultrasound examination of the fetus, and levels of various
proteins or hormones in the maternal blood [22]. However, for
various reasons, established NIPT is recognized as a potentially
highly effective screening test, but not as a test that can replace
current invasive prenatal diagnosis [23]. One of the vital reasons is
false positive results found with NIPTs. For example, Norton et al
[24] found one Tri21 false-positive and two Tri18 false-positive
results among 2888 high-risk cases when evaluating the perfor-
mance of NIPT for Tri21 and Tri18. Palomaki et al [25] found ﬁve
Tri18 false-positive and 16 Tri13 false-positive results among 1688
high-risk cases. The potential explanations for NIPT fetal karyotype
discordance include CPM, maternal mosaicism, co-twin demise,
maternal malignancy, and even laboratory error [19]. CPM is pre-
sent in 1e2% of ﬁrst trimester placentas [26]. Because fetal cfDNA in
maternal blood was thought to originate from placental apoptotic
trophoblasts [23,27], a majority of the reported NIPT false positive
or false negative results were the consequence of CPM [28,29],
which were involved in Tri13, Tri18, Tri21, and other chromosomes
[30e33]. In the present study, a Tri18 false positive NIPT result was
identiﬁed among 917 high-risk pregnancies after validation by full
karyotyping and FISH analysis. Medical records about the case
during pregnancy showed that the woman had no history of co-
twin demise or maternal malignancy. Considering that the kar-
yotyping of the woman and her fetus were both normal, the false
positive Tri18 was probably associated with CPM, although the
placenta was not used for further validation. Taken together, our
present ﬁndings and other emerged reports suggested that some
pregnancies might evolve with CPM that was sufﬁcient to cause
discordant NIPT results. Therefore, the positive result in NIPT
should be conﬁrmed by conventional invasive testing and kar-
yotyping, especially at early implementing stage.
The circulating cfDNA in maternal plasma is a combination of
maternal and fetal DNA, among which the fetal fraction is only
3e6% [17]. Therefore, abnormal maternal chromosome comple-
ments may lead to discordant NIPT results. Recent studies sug-
gested that low level maternal mosaicism resulted in variations of
the maternal contribution to circulating DNA, which could impact
NIPT results [34]. For example, Osborne et al [35] reported that a
malignant cell population could cause abnormal maternal cfDNA
that led to discordant NIPT results. Using massively parallel
sequencing, Wang et al [36] also found that maternal mosaicism
was a signiﬁcant contributor to discordant sex chromosomal an-
euploidies associated with NIPT. In the present study, NIPT ﬁndings
suggested a case with lower X chromosome concentration, but the
subsequent results of amniocentesis showed that the fetus was
normal (46, XY). Full karyotyping analysis of the maternal periph-
eral blood presented the maternal mosaicism for a missing X (45, X
and 46, XX), indicating that maternal mosaicism for aneuploidy
could result in discordant NIPT results. Therefore, maternal mosa-
icism must be considered as a confounding factor in NIPT. In
addition, the z-score, which was calculated to judge abnormality in
NIPT [10], of the X chromosome for this case was only 60% of the
normal value in the NIPT (data not shown), which was beyond the
scope of the impact of fetal cfDNA. Therefore, besides fetal aneu-
ploidies, NIPT may also be used to examine maternal mosaicism,
which may represent a new application of NIPT in the future.
In conclusion, our ﬁndings indicated that maternal mosaicism of
sex chromosomes could cause discordant sex chromosomalaneuploidies associated with NIPT. Therefore, we highly recom-
mend that, for the cases with abnormal results in NIPT, maternal
karyotype should be conﬁrmed to eliminate the inﬂuence of
maternal mosaicism.Conﬂicts of interest
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